SAN DIEGO, CA, APRIL 11, 2005 – Imagenetix, Inc., (OTCBB: IAGX – News), www.imagenetix.net, the developer of Celadrin, a natural compound for joint health, announced today that it has formed a partnership with Cymbiotics, Inc., located here, and Dr. Reddy’s Laboratories, (RDY), a major pharmaceutical company in Hyderabad, India, to launch Celadrin as a pharmaceutical in India. Celadrin has been approved for use as a drug in India to help reduce pain and inflammation in patients with joint conditions. In the United States, Celadrin is currently available as a dietary supplement at food, drug and mass retail stores.
According to Satish Reddy, Managing Director and COO of Dr. Reddy’s, “Dr. Reddy’s is emerging as the partner of choice for many innovators in healthcare because of our strong brand equity and extensive reach in the Indian market. Celadrin will enhance the treatment options available to medical practitioners in India, and we will be marketing the product in capsule and topical cream forms.”
Celadrin has been shown to be safe and effective in several double-blind, placebo-controlled clinical studies. In one such study conducted at the University of Connecticut, patients with knee joint conditions who used Celadrin in cream form showed significant improvement in quality of life measurements such as getting up from a seated position and stair climbing. A similar study determined that patients who took Celadrin orally improved knee range of motion and overall function. Both studies were published in the Journal of Rheumatology.
San Diego based Imagenetix, Inc. (Symbol: IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bio-ceutical products that enhance human health. The company develops, formulates and private-labels, proprietary over-the-counter topical creams, skin care products and nutritional supplements to be marketed globally through multiple channels of distribution.
Dr. Reddy’s Laboratories (NYSE: RDY) , www.drreddys.com, is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed in more than 100 countries.
Cymbiotics, Inc., based in San Diego, CA (USA), is a bio-pharmaceutical company that designs, develops, validates and introduces innovative disease-specific formulations in pain management, cardiovascular disease, periodontal disease, urinary incontinence and other inflammation management-related conditions. For more information, visit www.cymbiotics.net.